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Chen KS, Melikian CA, Chang EY,White TJ
Prescription Solutions, Costa Mesa, CA, USA
Diabetes is the fourth leading cause of death in the U.S.
and a major cause of blindness and heart disease. Studies
have demonstrated that tight glycemic control prevents
long-term microvascular/macrovascular complications
and may offset the associated substantial healthcare costs.
It has been demonstrated that 1.0% or greater improve-
ment in glycemic control resulted in cost saving of
$685–950/patient/year.
OBJECTIVES: To evaluate relationship between total
healthcare costs/utilization and changes in hemoglo-
binA1c (HbA1c) levels as a proxy for aggressive glycemic
control in type2 diabetic patients.
METHODS: A retrospective database analysis of labora-
tory data, pharmacy, and medical claims from a managed
care organization. Patients were selected from a compre-
hensive diabetes management clinic and had at least two
HbA1c tests that were between 3 and 9-months apart. All
patients had at least one oral anti-diabetic medication 
6-months prior to the ﬁrst HbA1c-test. Follow-up time
was time between two HbA1c tests and varied among
patients. Costs and utilization per-member-per-month
were compared between two cohorts, improving glycemic
control and worsening control stratiﬁed by HbA1c
changes (+/-1%). Outcomes were adjusted by age,
gender, co-morbid conditions, insulin-use, previous 
hospitalizations, physician visits, and prescription counts.
RESULTS: A total of 491 patients were identiﬁed, with
mean age of 70.8 (+/-10.5) years, 46.6% female (n =
229), and mean initial-HbA1c-level of 7.2% (+/-1.4; min
= 3.5, max = 13.8). Among them, 45.2% (n = 222) exhib-
ited improved-control and 48.9%(n = 240) exhibited
worsened-control. Patients with improved control had
signiﬁcantly higher adjusted average hospital costs than
those who worsened, $1,374 vs. $449 (p < 0.05).
Although not statistically signiﬁcant, patients with
improved in glycemic control had a higher average
number of anti-diabetic medications and physician visits
than those who worsened.
CONCLUSIONS: Improved glycemic control is associ-
ated with greater short-term healthcare utilization and
costs. Despite relatively well managed by the specialty-
clinic, patients showed further improvement in glycemic
control after hospital events. Future research is needed to
assess the long-term impact of glycemic control on health-
care costs.
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Type 2 diabetes causes a signiﬁcant economic burden on
the healthcare system in developed countries. Manage-
ment of macro and micro vascular complications con-
tributes as a major part of the direct costs.
OBJECTIVE: Estimate the incidence, prevalence, current
management and direct costs of cardiovascular and renal
complications in type 2 diabetic patients in the French
setting.
METHOD: A representative sample of 5,478 diabetic
patients was randomly selected from a database collect-
ing on-line medical data in a network of 650 French GPs.
Patients were selected on the criteria of at least two visits
to their physician on the period May 2000–April 2001.
A questionnaire was sent by mail to the GPs to collect
additional retrospective medical data on renal and cardio-
vascular complications. Corresponding costs were esti-
mated with unit costs from external sources.
RESULTS: The mean duration of diabetes was 10.0 years
and the mean age was 64 years. 29% of patients had a
Hb1c <6.5% and 39.2% in the range 6.5–8%. Annual
incidence of main complications (Myocardial Infarction,
Stroke, Congestive Heart Failure, Chronic Renal Insufﬁ-
ciency and End-Stage Renal Disease) were estimated in
the range 0.54 to 1%. 48% of the patients had BP >
140/80mmHg. The study showed that 26.7% of patients
had no Hb1c testing during the last year, 48% no LDL
cholesterol, 40% no creatininemia and 60% no ophthal-
mologic surveillance. The direct annual costs associated
with these complications were estimated 1 Billion Euros
for the whole French diabetic population (1.5 million).
Contribution to this cost was as following: stroke 36%,
MI 22.2%, CHF 17.4% and ESRD 24.4%.
CONCLUSION: Considering the current glycaemic
control and the quality of management of diabetic
patients, substantial beneﬁts could be achieved that
would reduce the extra-costs of complications.
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HEALTH SERVICES COST AND UTILIZATION
COMPARISONS AMONG LISPRO AND NON-
LISPRO REGULAR INSULIN USERS
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OBJECTIVE: To compare health services utilization and
cost among commercially insured users of lispro insulin
and non-lispro regular insulin.
